LIN9 and triple-negative breast carcinoma: For example, in the treatment of triple-negative breast cancer, paclitaxel resistance can be reversed by decreasing LIN9 expression, thus suggesting that paclitaxel resistance in triple-negative breast cancer can be reversed by combining bromo- and extra-terminal domain inhibitors with paclitaxel.